Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

Exclusion Criteria

• •Patient already underwent surgical total or partial tumor resection, or radiation therapy
• •Presence of leptomeningeal disease, gliomatosis cerebri, multifocal disease, bilateral cerebral hemisphere involvement ("butterfly" gliomas)
• •Patients at increased risk of neurologic decompensation
• •Continued use of high dose intravenous or oral corticosteroids, or \> 8milligrams per day of systemic dexamethasone
• •Uncontrolled tumor-related pain
• •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
• •Uncontrolled or symptomatic hypercalcemia
• •History of autoimmune disease or immune deficiency
• •History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
• •Significant cardiovascular disease
• •History of other malignancy within 1 year prior to screening
• •Severe infection within 4 weeks prior to initiation of study treatment
• •History of allogeneic stem cell or organ transplant
• •Prior treatment with CD137 agonists or immune checkpoint blockade therapies
• •Treatment with systemic immunostimulatory agents
• •Treatment with systemic immunosuppressive medication